Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow 0.00% Nasdaq Up0.52%

Delcath Systems, Inc. (DCTH)

3.86 Up 0.03(0.78%) 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Delcath Systems, Inc.
810 Seventh Avenue
35th Floor
New York, NY 10019
United States - Map
Phone: 212-489-2100
Fax: 212-489-2102

Index Membership:N/A
Industry:Drug Delivery
Full Time Employees:37

Business Summary 

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology in the United States and internationally. The company’s proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. It is primarily involved in the development of CHEMOSAT/Melphalan hepatic delivery system that administers concentrated regional chemotherapy to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Delcath Systems, Inc.

Key Executives 
Mr. Graham G. Miao M.S., M.B.A., Ph.D., 50
Interim Co-Chief Exec. Officer, Interim Co-Pres, Chief Financial Officer and Exec. VP
Mr. Peter J. Graham , 47
Chief Compliance Officer, Exec. VP and Gen. Counsel
Dr. Krishna Kandarpa M.D., PH.D., 63
Mr. Agustin V. Gago , 54
Dr. Jennifer K. Simpson Ph.D., M.S.N., C.R.N.P., 46
Interim Co-Chief Exec. Officer, Interim Co-Pres, Global Head of Bus. Operations and Exec. VP
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders